Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best of the IN VIVO Blog (10/2008)

This article was originally published in Start Up

Executive Summary

In Vivo's bloggers rant about Bayer and its acquisition of Direvo; group hugs at the annual conference of Private Equity Analysts in New York; and the complete and utter destruction of Wall Street.

You may also be interested in...



PSA: What We Have Here Is A Failure to Innovate

Discussion at FDC/Windhover's annual Pharmaceutical Strategic Alliances gathering in New York reflected the urgent need for the industry to adopt new models in order to spur innovation--in R&D, finance, business development, and commercial operations.

Private Biotech M&A Review: Has the Market Lost Steam?

In a still-frozen IPO market, acquisition has become the go-to exit for biotech VCs, but an analysis of the past four years' deals suggests the market may have peaked. Of more than 180 private biotech acquisitions since 2005, fewer than half in each year resulted in a reliable exit for investors, and those numbers are trending downward. Although the most active acquirers amounted to a list of the usual suspects, the bulk of acquisitions were conducted by a diverse set of smaller public and still-private firms. We also review the characteristics of those companies that have had success in terms of good exits for investors.

Devices Pique Private Equity's Interest

The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel